Lynne A. Bui

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 258 citations

Medicine, Oncology, Pharmacology +17

Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus

Lisa H. Butterfield, Syed M. Jilani, Nitya G. Chakraborty et al. · The Journal of Immunology · 1998 · 152 citations · Full text

Life Sciences, Immunology, Oncology +17

Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies

Jeffrey R. Infante, Josep Tabernero, Howard A. Burris et al. · Cancer Research · 2012 · 85 citations

Medicine, Oncology, Pharmacology +15

<i>In Vivo</i> Therapy of Hepatocellular Carcinoma with a Tumor-Specific Adenoviral Vector Expressing Interleukin-2

Lynne A. Bui, Lisa H. Butterfield, John Y. Kim et al. · Human Gene Therapy · 1997 · 78 citations

Medicine, Cancer Biology, Oncology +14

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Neil P. Shah, Patrycja Olszynski, Lubomir Sokol et al. · Blood · 2008 · 68 citations

Medicine, Hematology, Pharmacology +7